- The market is driven by the rising incidence of pemphigus vulgaris, growing awareness of autoimmune diseases, and advancements in biologic therapies, leading to increased demand for effective treatment options and improved patient outcomes globally
- Key factors influencing market growth include expanding healthcare infrastructure, rising healthcare expenditure, government support for rare disease research, and ongoing clinical trials focused on novel therapeutics targeting pemphigus vulgaris management
- North America is expected to dominate the pemphigus vulgaris market with a 45.93% revenue share in 2025, supported by advanced healthcare infrastructure, high patient awareness, robust research and development activities, widespread availability of biologic therapies, and strong government initiatives promoting rare disease treatment
- Asia-Pacific is expected to be the fastest-growing region in the pemphigus vulgaris market during the forecast period, fueled by increasing healthcare investments, growing patient population, rising awareness, improved diagnostic facilities, and expanding access to advanced treatments across emerging economies
- The treatment segment is expected to dominate the pemphigus vulgaris market with a 66.33% share in 2025, driven by increasing demand for biologic therapies, rising prevalence of autoimmune diseases, advancements in treatment options, and growing patient preference for effective, targeted therapies
